Treatment and outcomes of ewing sarcoma in Turkish Adults: A single centre experience


Creative Commons License

Seker M. M., Kos T., Ozdemir N., Seker A., AKSOY S., Uncu D., ...Daha Fazla

Asian Pacific Journal of Cancer Prevention, cilt.15, sa.1, ss.327-330, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.7314/apjcp.2014.15.1.327
  • Dergi Adı: Asian Pacific Journal of Cancer Prevention
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.327-330
  • Anahtar Kelimeler: Adult cases, Ewing sarcoma, prognosis, Turkey, PRIMITIVE NEUROECTODERMAL TUMOR, PROGNOSTIC-FACTORS, NEOADJUVANT CHEMOTHERAPY, STANDARD CHEMOTHERAPY, RECEPTOR ANTIBODY, BONE, FAMILY, THERAPY, DIAGNOSIS, CHILDREN
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Background: Ewing sarcoma is a small round cell tumor arising from soft tissue and bone that predominantly affects children and adolescents. The most unfavorable prognostic factor is the presence of distant metastasis at the time of diagnosis. Materials and Methods: The records of 26 Ewing sarcoma patients (14 male, 12 female) were re-evaluated retrospectively. Results: The median age was 26.5 (19-42) years. Eight patients (31%) showed a primary tumor in their extremities, 8 (31%) in the thorax, 4 (15%) at the vertebra, 4 (15%) in the head and neck, and 2 (8%) in the abdomen. Five patients (19%) had distant metastasis at diagnosis. The median progression-free survival was 72 months and 10 months in localized and metastatic disease, respectively (p=0.005). The overall survival rate was 19 months in metastatic disease, and the 5-year overall survival rate was 64% in localized disease (p=0.006). Patients who had localized disease in the extremities and were under age 30 had a favorable prognosis. Conclusions: Although Ewing sarcoma is a tumor affecting children and adolescents, it may be seen in adults, where the prognosis is generally worse. Although it is a highly malignant tumor, it is possible to achieve improved survival with combined modality treatments.